GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: DEPO
Buy $33

Depomed, Inc. (NASDAQ: DEPO) upgraded to Buy with price target $33 by WallachBeth

Wednesday,  Nov 11, 2015  8:25 AM ET by Dave Ficere

WallachBeth upgraded Depomed, Inc. (NASDAQ: DEPO) to Buy with price
target $33. Previously WallachBeth rated Hold with price target $33 Depomed, Inc. (NASDAQ: DEPO) on 07/24/2015, when the stock price was $32.73.

Depomed, Inc. (Depomed) is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that are based on oral drug delivery technologies. Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride extended release tablets), which is a once-daily treatment for adults with type 2 diabetes that it commercializes in the United States with Santarus, Inc. (Santarus). ProQuin XR (ciprofloxacin hydrochloride extended release tablets), which is a once-daily treatment for uncomplicated urinary tract infections that Depomed commercializes in the United States with Watson Pharma (Watson).

WallachBeth



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy